Do analysts prefer CANF or BPTSY?

Can-Fite BioPharma currently has a consensus target price of $44.00, indicating a potential upside of 1,253.85%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, CANF or BPTSY?

Can-Fite BioPharma has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Can-Fite BioPharma $405K 5.26 -$7.63M -$22.80 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is CANF or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Biophytis N/A N/A N/A

Do analysts recommend BPTSY or SHPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BPTSY or SHPH?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A

Is BPTSY or SHPH more profitable?

Biophytis' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Shuttle Pharmaceuticals N/A -408.34% -138.15%

Do analysts prefer BPTSY or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BPTSY or CDT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is BPTSY or CDT more profitable?

Biophytis' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A CDT Equity N/A -4,263.33% -529.91%

Which has higher earnings and valuation, ORGS or BPTSY?

Biophytis has lower revenue, but higher earnings than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 2.90 -$55.36M -$11.51 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is ORGS or BPTSY more profitable?

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Biophytis N/A N/A N/A

Which has preferable valuation and earnings, BPTH or BPTSY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is BPTH or BPTSY more profitable?

Biophytis' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Biophytis N/A N/A N/A

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)

As of 07/10/2026

Compare

BPTSY vs. CANF, SHPH, CDT, ORGS, and BPTH

Should you buy Biophytis stock or one of its competitors? MarketBeat compares Biophytis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biophytis include Can-Fite BioPharma (CANF), Shuttle Pharmaceuticals (SHPH), CDT Equity (CDT), Orgenesis (ORGS), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical products" industry.

How does Biophytis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Can-Fite BioPharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Can-Fite BioPharma currently has a consensus target price of $44.00, indicating a potential upside of 1,253.85%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Can-Fite BioPharma had 6 more articles in the media than Biophytis. MarketBeat recorded 6 mentions for Can-Fite BioPharma and 0 mentions for Biophytis. Can-Fite BioPharma's average media sentiment score of 0.42 beat Biophytis' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Biophytis	Neutral

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.26	-$7.63M	-$22.80	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Summary

Can-Fite BioPharma beats Biophytis on 8 of the 10 factors compared between the two stocks.

How does Biophytis compare to Shuttle Pharmaceuticals?

Biophytis (NASDAQ:BPTSY) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Biophytis' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A

In the previous week, Shuttle Pharmaceuticals had 9 more articles in the media than Biophytis. MarketBeat recorded 9 mentions for Shuttle Pharmaceuticals and 0 mentions for Biophytis. Shuttle Pharmaceuticals' average media sentiment score of 0.23 beat Biophytis' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
Shuttle Pharmaceuticals	Neutral

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Shuttle Pharmaceuticals beats Biophytis on 6 of the 9 factors compared between the two stocks.

How does Biophytis compare to CDT Equity?

Biophytis (NASDAQ:BPTSY) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

In the previous week, CDT Equity had 3 more articles in the media than Biophytis. MarketBeat recorded 3 mentions for CDT Equity and 0 mentions for Biophytis. CDT Equity's average media sentiment score of 0.55 beat Biophytis' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
CDT Equity	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biophytis' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
CDT Equity	N/A	-4,263.33%	-529.91%

Summary

CDT Equity beats Biophytis on 5 of the 9 factors compared between the two stocks.

How does Biophytis compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Biophytis has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	2.90	-$55.36M	-$11.51	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Orgenesis has a beta of 3.14, meaning that its stock price is 214% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Biophytis	N/A	N/A	N/A

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Biophytis	Neutral

Summary

Biophytis beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Biophytis	Neutral

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bio-Path has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

Biophytis' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Biophytis	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Summary

Biophytis beats Bio-Path on 4 of the 6 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTSY vs. The Competition

Export

Metric	Biophytis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$586K	$776.41M	$7.09B	$12.66B
Dividend Yield	N/A	4.84%	2.68%	8.00%
P/E Ratio	N/A	1.64	27.42	24.53
Price / Sales	N/A	115.29	528.33	96.17
Price / Cash	N/A	20.06	48.47	60.03
Price / Book	-0.02	8.45	10.88	6.38
Net Income	-$18.43M	-$2.88M	$3.59B	$331.87M
7 Day Performance	N/A	-0.94%	-0.26%	0.37%
1 Month Performance	N/A	2.05%	4.55%	0.59%
1 Year Performance	-81.20%	44.81%	29.86%	22.26%

Biophytis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
CANF Can-Fite BioPharma	2.341 of 5 stars	$3.48 -8.4%	$44.00 +1,164.4%	-84.3%	$2.28M	$405K	N/A	8	Analyst Revision
SHPH Shuttle Pharmaceuticals	0.9347 of 5 stars	$3.26 -6.9%	N/A	-92.7%	$2.23M	N/A	N/A	5	News Coverage Short Interest Increase Gap Down
CDT CDT Equity	0.4419 of 5 stars	$0.44 -3.1%	N/A	-99.9%	$2.21M	N/A	N/A	3	Short Interest Increase
ORGS Orgenesis	N/A	$0.40 flat	N/A	-65.2%	$2.07M	$662K	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biophytis (BPTSY) Competitors

BPTSY vs. CANF, SHPH, CDT, ORGS, and BPTH

How does Biophytis compare to Can-Fite BioPharma?

Summary

How does Biophytis compare to Shuttle Pharmaceuticals?

Summary

How does Biophytis compare to CDT Equity?

Summary

How does Biophytis compare to Orgenesis?

Summary

How does Biophytis compare to Bio-Path?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biophytis (BPTSY) Competitors

BPTSY vs. CANF, SHPH, CDT, ORGS, and BPTH

How does Biophytis compare to Can-Fite BioPharma?

Which has more risk and volatility, CANF or BPTSY?

Is CANF or BPTSY more profitable?

Do insiders & institutionals believe in CANF or BPTSY?

Do analysts prefer CANF or BPTSY?

Does the media refer more to CANF or BPTSY?

Which has stronger valuation and earnings, CANF or BPTSY?

Summary

How does Biophytis compare to Shuttle Pharmaceuticals?

Do analysts recommend BPTSY or SHPH?

Which has more risk & volatility, BPTSY or SHPH?

Is BPTSY or SHPH more profitable?

Which has stronger earnings & valuation, BPTSY or SHPH?

Does the media favor BPTSY or SHPH?

Do institutionals and insiders have more ownership in BPTSY or SHPH?

Summary

How does Biophytis compare to CDT Equity?

Which has more volatility and risk, BPTSY or CDT?

Which has higher earnings & valuation, BPTSY or CDT?

Does the media favor BPTSY or CDT?

Do analysts prefer BPTSY or CDT?

Do insiders and institutionals have more ownership in BPTSY or CDT?

Is BPTSY or CDT more profitable?

Summary

How does Biophytis compare to Orgenesis?

Which has higher earnings and valuation, ORGS or BPTSY?

Which has more risk & volatility, ORGS or BPTSY?

Is ORGS or BPTSY more profitable?

Do institutionals & insiders hold more shares of ORGS or BPTSY?

Does the media refer more to ORGS or BPTSY?

Summary

How does Biophytis compare to Bio-Path?

Does the media favor BPTH or BPTSY?

Do insiders & institutionals have more ownership in BPTH or BPTSY?

Which has more risk & volatility, BPTH or BPTSY?

Is BPTH or BPTSY more profitable?

Which has preferable valuation and earnings, BPTH or BPTSY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools